Abstract
Lung cancer is a disease that influences human health and has become a leading cause of cancer mortality worldwide. However, it is frequently diagnosed at the advanced stage. It is necessary by means of biology to identify specific lung tumor biomarkers with high sensitivity. Glycosylation is one of the most important post-translational modifications and is related to many different diseases. It is involved in numerous essential biological processes, such as cell proliferation, differentiation, migration, cell-cell integrity and recognition, and immune modulation. However, little was known about deregulation of glycosylation in lung cancer and contribution to tumor–microenvironment interactions. Among the numerous glycosylations, fucosylation is the most common modification of glycoproteins and glycosylated oligosaccharides. Increased levels of fucosylation have been detected in various pathological conditions, as well as in lung cancer. In this article, we reviewed the role of fucosylation in lung cancer. We highlighted some of the fucosylation alterations currently being pursued in sera or tissues of lung cancer patients. Moreover, we elaborated on the regulation mechanism of fucosylation in proliferative invasion and metastasis of lung tumor cells. In summary, alterations in fucosylation provide potential biomarkers and therapeutic targets in lung cancer.
Highlights
Lung cancer, a primary cause of death, has increasing incidence and mortality rates worldwide [1,2,3]
It is suggested that the aberrantly fucosylated target glycoproteins acid glycoprotein (AGP) and CP could be quantitatively identified as potential biomarkers of ADC. These results indicated that the level of core fucosylation, FUT8, and core-fucosylated products may provide new insights into the therapeutic targets of NSCLC (Table 1)
Less is known about the fucosylation in small cell lung cancer (SCLC), it is characterized by more higher malignancy, more often remote metastasis and poor prognosis
Summary
A primary cause of death, has increasing incidence and mortality rates worldwide [1,2,3]. Commonly used the methods for early diagnosis of lung cancer are Magnetic Resonance Imaging (MRI), Positron Emission TomographyComputed Tomography (PET-CT), Endo-Bronchial Ultra-Sound (EBUS), Endocytoscopy (EC), Transbronchial Needle Aspiration (TBNA), and combined Testing of Serum Tumor Markers et al there is a favorable survival rate in patients with earl stage lung cancer. As a result, searching for new biomarkers with high sensitivity and specificity to lung cancer will provide us with critical evidence in early diagnosis, therapy guidance, and prognosis monitoring. It has significance in increasing lung cancer survivability
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
